AGENCY:
Food and Drug Administration, HHS.
ACTION:
Notice.
SUMMARY:
The Food and Drug Administration (FDA or Agency) is withdrawing approval of 16 new drug applications (NDAs) from multiple applicants. The applicants notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.
DATES:
Approval is withdrawn as of May 1, 2019.
FOR FURTHER INFORMATION CONTACT:
Kimberly Lehrfeld, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 6226, Silver Spring, MD 20993-0002, 301-796-3137.
SUPPLEMENTARY INFORMATION:
The applicants listed in the table have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications under the process in § 314.150(c) (21 CFR 314.150(c)). The applicants have also, by their requests, waived their opportunity for a hearing. Withdrawal of approval of an application or abbreviated application under § 314.150(c) is without prejudice to refiling.
| Application No. | Drug | Applicant |
|---|---|---|
| NDA 007883 | Antabuse (disulfiram) Tablets, 250 milligrams (mg) and 500 mg | Teva Women's Health, Inc., 41 Moores Rd., P.O. Box 4011, Frazer, PA 19355. |
| NDA 011324 | Sinografin (diatrizoate meglumine and iodipadmide meglumine) Injection, 52.7%/26.8% | Bracco Diagnostic Inc., 259 Prospect Plains Rd., Bldg. H, Monroe Township, NJ 08831. |
| NDA 018932 | ReVia (naltrexone hydrochloride) Tablets, 50 mg | Teva Women's Health, Inc. |
| NDA 019880 | Paraplatin (carboplatin) Injection, 50 mg/vial, 150 mg/vial, and 450 mg/vial | Corden Pharma Latina S.p.A., c/o Clinipace, Inc., 4840 Pearl East Circle, Suite 201E, Boulder, CO 80301. |
| NDA 020261 | Lescol (fluvastatin sodium) Capsules, 20 mg and 40 mg | Novartis Pharmaceuticals Corp., One Health Plaza, East Hanover, NJ 07936-1080. |
| NDA 020452 | Paraplatin (carboplatin) Injection in multiple dose vials, 50 mg/5 milliliters (mL), 150 mg/15 mL, 450 mg/45 mL, and 600 mg/60 mL | Corden Pharma Latina S.p.A. |
| NDA 021431 | Campral (acamprosate calcium) Delayed-Release Tablets, 333 mg | Allergan Sales, LLC., 5 Giralda Farms, Madison, NJ 07940. |
| NDA 021551 | Halflytely and Bisacodyl Tablet Bowel Prep Kit (polyethylene glycol 3350, potassium chloride, sodium bicarbonate, and sodium chloride powder for oral solution, 210 grams (g)/0.74 g/2.86 g/5.6 g; bisacodyl delayed-release tablet, 5 mg) | Braintree Laboratories, Inc., 60 Columbian St. West, P.O. Box 850929, Braintree, MA 02185. |
| NDA 021823 | Actonel with Calcium (risedronate sodium tablets, 35 mg; calcium carbonate tablets USP, equivalent to 500 mg base) | Warner Chilcott Co., LLC., 100 Enterprise Dr., Rockaway, NJ 07866. |
| NDA 021905 | Valtropine (somatropin) for Injection, 5 mg/vial | LG Chem, Ltd., c/o Parexel International, LLC., 4600 East-West Highway, Suite 350, Bethesda, MD 20814. |
| NDA 022396 | Dyloject (diclofenac sodium) Injection, 37.5 mg/mL | Javelin Pharmaceuticals, Inc., c/o Hospira, Inc., 275 North Field Dr., Dept. 0389, HI-3S, Lake Forest, IL 60045. |
| NDA 050619 | Mycostatin (nystatin) Pastilles, 200,000 Units | Delcor Asset Corp., c/o Mylan, Inc., 781 Chestnut Ridge Rd., P.O. Box 4310, Morgantown, WV 26504-4310. |
| NDA 050739 | Omnicef (cefdinir) Capsules, 300 mg | AbbVie Inc., 1 North Waukegan Rd., North Chicago, IL 60064. |
| NDA 050749 | Omnicef (cefdinir) Oral Suspension, 125 mg/5 mL and 250 mg/5 mL | Do. |
| NDA 050757 | PrevPAC (amoxicillin capsules USP, 500 mg; clarithromycin tablets USP, 500 mg; and lansoprazole delayed-release capsules, 30 mg) | Takeda Pharmaceuticals U.S.A., Inc., One Takeda Parkway, Deerfield, IL 60015. |
| NDA 202356 | Docetaxel Injection, 20 mg/2 mL, 80 mg/8 mL, 130 mg/13 mL, and 200 mg/20 mL | Pfizer Inc., 235 East 42nd St., New York, NY 10017. |
Therefore, approval of the applications listed in the table, and all amendments and supplements thereto, is hereby withdrawn as of May 1, 2019. The drug product strengths listed in the table include all strengths FDA has identified as being previously approved under these NDAs. In each case, approval of the entire application is withdrawn, including any strengths inadvertently missing from the table. Introduction or delivery for introduction into interstate commerce of products without approved new drug applications violates section 301(a) and (d) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 331(a) and (d)). Drug products that are listed in the table that are in inventory on May 1, 2019 may continue to be dispensed until the inventories have been depleted or the drug products have reached their expiration dates or otherwise become violative, whichever occurs first.
Dated: March 26, 2019.
Lowell J. Schiller,
Acting Associate Commissioner for Policy.
[FR Doc. 2019-06237 Filed 3-29-19; 8:45 am]
BILLING CODE 4164-01-P